Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

suicide prevention drug

- PMLiVE

Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke

TNKase is the first stroke medicine to be approved by the regulator in almost three decades

- PMLiVE

BeiGene’s Tevimbra approved by FDA for first-line oesophageal cancer use

Oesophageal squamous cell carcinoma accounts for nearly 90% of all oesophageal cancers

- PMLiVE

FDA approves Mirum’s Ctexli as first treatment for rare lipid storage disease CTX

The progressive genetic disorder affects up to 2,000 people in the US

- PMLiVE

FDA grants RMAT designation to AskBio’s Parkinson’s gene therapy candidate

The progressive neurodegenerative disease affects more than ten million people worldwide

- PMLiVE

Sanofi and Regeneron’s Dupixent granted FDA priority review for bullous pemphigoid

Approximately 27,000 adults in the US are living with uncontrolled cases of the skin disease

EU flag

EC approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha

- PMLiVE

FDA approves Bavarian Nordic’s chikungunya vaccine for individuals aged from 12 years

The mosquito-borne viral disease has been reported across many popular travel destinations

- PMLiVE

GSK’s five-in-one meningococcal vaccine Penmenvy granted FDA approval

It is hoped that the combination vaccine will simplify delivery and lead to higher uptake

- PMLiVE

Roche’s Evrysdi tablet formulation granted FDA approval for spinal muscular atrophy

The progressive neuromuscular disease affects approximately one in every 10,000 babies globally

- PMLiVE

Pfizer granted FDA approval for Adcetris combination in large B-cell lymphoma

Up to 70% of patients with this form of non-Hodgkin lymphoma are diagnosed with advanced disease

- PMLiVE

FDA approves SpringWorks Therapeutics’ Gomekli to treat neurofibromatosis type 1

The rare genetic disorder affects approximately 100,000 people in the US

- PMLiVE

AbbVie announces FDA approval of antibiotic combination for intra-abdominal infections

Antimicrobial resistance has been declared by WHO as one of the top ten threats to global health

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links